Hou et al., by generating two bsAbs (PD-1/c-Met DVD-Ig and IgG-scFv) both targeting PD-1 on T cells and MET on tumor cells, showed several advantages such as a higher specific binding capacity provided by the additional Ag-binding units and a reduction in the risk of off-target FcγR-mediated ADCC due to low affinity to Fcγ receptors [149]. The gene discussed is PDCD1; the disease is neoplasm.